Antiphospholipid Antibodies and APS Nephropathy

Rohan Willis*, Emilio B Gonzalez

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 7653
Abstract HTML Views: 2385
PDF Downloads: 1118
ePub Downloads: 733
Total Views/Downloads: 11889
Unique Statistics:

Full-Text HTML Views: 3496
Abstract HTML Views: 1248
PDF Downloads: 801
ePub Downloads: 527
Total Views/Downloads: 6072

Creative Commons License
© Willis and Gonzalez; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Antiphospholipid Standardization Laboratory, Division of Rheumatology, Department of Internal Medicine, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555-0883, USA; Tel: 409.772.0225; Fax: 409.772.0226; E-mail:


The presence of pathogenic antiphospholipid antibodies (aPL) is the characterizing feature of the antiphospholipid syndrome (APS), mediating the recurrent pregnancy loss and thrombosis typical of the disease through its action on various antigenic targets. APS nephropathy is the characteristic clinico-athological manifestation of renal involvement in APS and occurs as a result of vaso-occlusive disease in the intrarenal vasculature. The typical clinical features and morphological lesions of APS nephropathy have been well characterized and several studies have established a link between these features and the presence of various aPL. In this review, we outline the proposed pathophysiological mechanisms of aPL-mediated thrombosis, the characteristic clinical and morphological features of APS nephropathy and the evidence linking aPL action to the occurrence of APS nephropathy.

Keywords: Antiphospholipid syndrome, antiphospholipid antibodies, nephropathy.